본문으로 건너뛰기
← 뒤로

Electromagnetic Wireless Remote Control of Reprogramming Immune Dysfunction via N-Doped Carbon Dots-Mesoporous Silica-Mediated Cuproptosis and Dendritic Cell Retention.

1/5 보강
Advanced healthcare materials 📖 저널 OA 25.6% 2021: 1/1 OA 2022: 0/1 OA 2023: 1/1 OA 2024: 2/7 OA 2025: 8/20 OA 2026: 19/91 OA 2021~2026 2026 Vol.15(6) p. e02817 OA
Retraction 확인
출처

Lien HW, Kuo YY, Chang YH, Huynh TMH, Yalamandala BN, Li TC, Iao HM, Pan WC, Lee AY, Chiang WH, Hu SH

📝 환자 설명용 한 줄

Dendritic cells (DCs) are key initiators of antitumor immune responses.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Lien HW, Kuo YY, et al. (2026). Electromagnetic Wireless Remote Control of Reprogramming Immune Dysfunction via N-Doped Carbon Dots-Mesoporous Silica-Mediated Cuproptosis and Dendritic Cell Retention.. Advanced healthcare materials, 15(6), e02817. https://doi.org/10.1002/adhm.202502817
MLA Lien HW, et al.. "Electromagnetic Wireless Remote Control of Reprogramming Immune Dysfunction via N-Doped Carbon Dots-Mesoporous Silica-Mediated Cuproptosis and Dendritic Cell Retention.." Advanced healthcare materials, vol. 15, no. 6, 2026, pp. e02817.
PMID 41189399 ↗

Abstract

Dendritic cells (DCs) are key initiators of antitumor immune responses. However, dendritic cells frequently exhibit compromised antigen-presenting capabilities and adopt an immunoregulatory or tolerogenic phenotype, contributing to immune suppression in tumor microenvironment, severely limiting their efficacy. To overcome this, a pH-responsive lung-metastasis-targeted wirelessly charging-boosted dual-catalyst nanoplatform composed of tumor-penetrating solid lipids/polymer-coated N-doped carbon dots/mesoporous silica nanoparticles (CMS), loaded with cuproptosis-inducing agents (elesclomol-copper, EsCu) is developed for initiating a self-cascade immune response and dendritic cell retention. Upon exposure to alternating magnetic fields (AMFs), N-doped carbon dots can generate the currents and enhance cuproptosis through mechanisms consistent with Kelvin's force laws, boosting catalytic activity. Intravenously injected CMS selectively accumulates at metastatic tumor sites through pH-triggered charge switching, while the positive charge also promotes the release of cell-cell interactions. At tumor site, Es and Cu are released in response to intracellular conditions and AMF stimulation, inducing cuproptosis in cancer cells and disrupting immune evasion. This cytotoxicity is paired with in situ antigen release, which CMS carriers deliver to reprogram DCs, initiating sustained immune activation. When combined with immune checkpoint blockade (anti-PD-1), the CMS system effectively suppresses lung metastases and extends survival beyond 60 days.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기